Saniona AB Market Cap ($157.31 Million)
Market Cap & Net Worth: Saniona AB (SANION)
Saniona AB market cap. Saniona AB (ST:SANION) has a market capitalization of $157.31 Million (Skr1.46 Billion) as of November 5, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #17281 globally and #294 in its home market, demonstrating a -5.19% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Saniona AB's stock price Skr10.59 by its total outstanding shares 138030134 (138.03 Million). Also see how efficiently does Saniona AB generate cash for how efficiently the company converts equity into cash flow.
Saniona AB Market Cap History (2015–2026)
Saniona AB market cap history from 2015 to 2026. Data shows change from $234.05 Million to $157.31 Million (-0.95% CAGR). Check current stock price of Saniona AB for real-time trading data and today's change.
Saniona AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Saniona AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Saniona AB equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.72x
Saniona AB's market cap is 0.72 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.11x
Saniona AB's market cap is 1.11 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $592.34 Million | $74.92 Million | $2.22 Million | 7.91x | 267.18x |
| 2017 | $443.53 Million | $20.69 Million | -$49.19 Million | 21.43x | N/A |
| 2018 | $462.31 Million | $54.88 Million | -$41.06 Million | 8.42x | N/A |
| 2019 | $381.75 Million | $2.66 Million | -$75.79 Million | 143.62x | N/A |
| 2020 | $306.00 Million | $8.20 Million | -$73.43 Million | 37.33x | N/A |
| 2021 | $131.46 Million | $10.48 Million | -$410.90 Million | 12.55x | N/A |
| 2022 | $45.53 Million | $15.28 Million | -$245.36 Million | 2.98x | N/A |
| 2023 | $59.57 Million | $16.84 Million | -$95.81 Million | 3.54x | N/A |
| 2024 | $119.43 Million | $334.67 Million | $188.71 Million | 0.36x | 0.63x |
| 2025 | $314.91 Million | $434.40 Million | $284.67 Million | 0.72x | 1.11x |
Competitor Companies of SANION by Market Capitalization
Companies near Saniona AB in the global market cap rankings as of November 5, 2026. Also see Saniona AB (SANION) total assets for a full breakdown of the balance sheet.
Key companies related to Saniona AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Saniona AB (2015–2026)
Market capitalization of Saniona AB from 2015 to today. Between 2015 and today, Saniona AB's market cap moved from $234.05 Million to $ 157.31 Million, with a yearly change of -0.95%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr157.31 Million | -50.05% |
| 2025 | Skr314.91 Million | +163.68% |
| 2024 | Skr119.43 Million | +100.50% |
| 2023 | Skr59.57 Million | +30.83% |
| 2022 | Skr45.53 Million | -65.37% |
| 2021 | Skr131.46 Million | -57.04% |
| 2020 | Skr306.00 Million | -19.84% |
| 2019 | Skr381.75 Million | -17.43% |
| 2018 | Skr462.31 Million | +4.23% |
| 2017 | Skr443.53 Million | -25.12% |
| 2016 | Skr592.34 Million | +153.09% |
| 2015 | Skr234.05 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Saniona AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $157.31 Million USD |
| MoneyControl | $157.31 Million USD |
| MarketWatch | $157.31 Million USD |
| marketcap.company | $157.31 Million USD |
| Reuters | $157.31 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Saniona AB
Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical t… Read more